Welcome to Dividend.com
Please help us personalize your experience.
Select the one that best describes you

Virtus LifeSci Biotech Clinical Trials ETF

etf
BBC
Dividend policy
Suspended
Price as of:
$ N/A 0
primary theme
Health Care Sector Equity
BBC (ETF)

Virtus LifeSci Biotech Clinical Trials ETF

Dividend policy
Suspended
Price as of:
$ N/A 0
primary theme
Health Care Sector Equity
BBC (ETF)
Virtus LifeSci Biotech Clinical Trials ETF
Dividend policy
Suspended
Price as of:
$ N/A 0
primary theme
Health Care Sector Equity

BBC - Snapshot

Vitals

  • YTD Return 22.0%
  • 3 Yr Annualized Return 12.4%
  • 5 Yr Annualized Return 7.7%
  • Net Assets $37 M
  • Holdings in Top 10 14.4%

52 WEEK LOW AND HIGH

N/A
N/A
N/A

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.79%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 67.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) N/A
  • IRA N/A

Fund Classification

  • Primary Theme Health Care Sector Equity
  • Fund Type Exchange Traded Fund
  • Investment Style Health

Compare BBC to Popular Health Care Sector Equity Funds

Overview

Next Dividend

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Dividend.com Ratings*

$107.45

+1.29%

$12.74 B

1.20%

$1.27

blocked
blocked
blocked

11.99%

-

Compare BBC to Popular Health Care Sector Equity ETFs

Overview

Next Dividend

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Dividend.com Ratings*

$109.44

+0.92%

$22.44 B

1.52%

$1.65

blocked
blocked
blocked

7.44%

-

$215.00

+1.36%

$12.74 B

1.20%

$2.55

blocked
blocked
blocked

12.13%

-

$143.22

+3.07%

$8.76 B

0.22%

$0.30

blocked
blocked
blocked

18.84%

-

$310.95

+0.97%

$8.15 B

0.27%

$0.84

blocked
blocked
blocked

17.64%

-

$131.46

+3.66%

$5.33 B

0.08%

$0.11

blocked
blocked
blocked

38.22%

-

BBC - Profile

Distributions

  • YTD Total Return 22.0%
  • 3 Yr Annualized Total Return 12.4%
  • 5 Yr Annualized Total Return 7.7%
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.50%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Virtus LifeSci Biotech Clinical Trials ETF
  • Fund Family Name
    Virtus
  • Inception Date
    Dec 16, 2014
  • Shares Outstanding
    950004
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Matthew Brown

Fund Description

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.


BBC - Performance

Return Ranking - Trailing

Period BBC Return Category Return Low Category Return High Rank in Category (%)
YTD 22.0% -4.9% 137.5% 26.09%
1 Yr 47.5% -1.4% 132.6% 5.63%
3 Yr 12.4%* 0.8% 40.7% 37.06%
5 Yr 7.7%* -0.7% 29.6% 57.14%
10 Yr N/A* 8.1% 19.7% N/A

* Annualized

Return Ranking - Calendar

Period BBC Return Category Return Low Category Return High Rank in Category (%)
2019 63.8% 3.8% 63.8% 0.69%
2018 -18.3% -49.7% 21.5% 89.78%
2017 54.4% -59.8% 54.4% 0.74%
2016 -36.6% -36.6% 11.6% 100.00%
2015 4.7% -62.4% 27.9% 22.95%

Total Return Ranking - Trailing

Period BBC Return Category Return Low Category Return High Rank in Category (%)
YTD 22.0% -4.9% 137.5% 26.09%
1 Yr 47.5% -6.5% 132.6% 5.63%
3 Yr 12.4%* -0.3% 40.7% 33.57%
5 Yr 7.7%* -0.7% 29.6% 55.71%
10 Yr N/A* 8.1% 19.7% N/A

* Annualized

Total Return Ranking - Calendar

Period BBC Return Category Return Low Category Return High Rank in Category (%)
2019 63.8% 3.8% 63.8% 0.69%
2018 -18.3% -25.3% 22.2% 91.24%
2017 54.4% -10.8% 54.4% 0.74%
2016 -36.6% -36.6% 11.6% 100.00%
2015 4.7% -16.6% 27.9% 59.02%

BBC - Holdings

Concentration Analysis

BBC Category Low Category High BBC % Rank
Net Assets 37 M 3.74 M 46 B 80.81%
Number of Holdings 130 24 426 16.28%
Net Assets in Top 10 5.31 M 952 K 19.6 B 91.28%
Weighting of Top 10 14.35% 14.0% 75.7% 99.42%

Top 10 Holdings

  1. Sorrento Therapeutics Inc 1.91%
  2. MyoKardia Inc 1.88%
  3. Mirati Therapeutics Inc 1.68%
  4. Kura Oncology Inc 1.52%
  5. Novavax Inc 1.40%
  6. BioNTech SE ADR 1.39%
  7. Arrowhead Pharmaceuticals Inc 1.38%
  8. Denali Therapeutics Inc 1.37%
  9. AnaptysBio Inc 1.26%
  10. Kodiak Sciences Inc 1.24%

Asset Allocation

Weighting Return Low Return High BBC % Rank
Stocks
99.36% 61.47% 102.50% 33.14%
Cash
0.64% -0.01% 32.46% 59.88%
Preferred Stocks
0.00% 0.00% 6.63% 52.33%
Other
0.00% -2.50% 6.07% 58.14%
Convertible Bonds
0.00% 0.00% 0.06% 44.19%
Bonds
0.00% 0.00% 16.11% 45.93%

Stock Sector Breakdown

Weighting Return Low Return High BBC % Rank
Healthcare
99.49% 61.81% 100.00% 50.58%
Basic Materials
0.51% 0.00% 2.60% 21.51%
Utilities
0.00% 0.00% 0.00% 43.02%
Technology
0.00% 0.00% 15.86% 52.33%
Real Estate
0.00% 0.00% 6.03% 48.84%
Industrials
0.00% 0.00% 5.94% 48.84%
Financial Services
0.00% 0.00% 3.31% 65.12%
Energy
0.00% 0.00% 0.00% 43.02%
Communication Services
0.00% 0.00% 4.69% 45.93%
Consumer Defense
0.00% 0.00% 34.31% 48.26%
Consumer Cyclical
0.00% 0.00% 1.09% 46.51%

Stock Geographic Breakdown

Weighting Return Low Return High BBC % Rank
US
89.38% 47.91% 99.98% 24.42%
Non US
9.98% 0.00% 43.79% 70.93%

BBC - Expenses

Operational Fees

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.79% 0.08% 25.14% 66.27%
Management Fee 0.79% 0.00% 1.25% 69.77%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.40% N/A

Sales Fees

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 67.00% 0.70% 252.00% 83.44%

BBC - Distributions

Dividend Yield Analysis

BBC Category Low Category High BBC % Rank
Dividend Yield 0.00% 0.00% 3.15% 51.16%

Dividend Distribution Analysis

BBC Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Semi-Annually Annually

Net Income Ratio Analysis

BBC Category Low Category High BBC % Rank
Net Income Ratio -0.50% -2.53% 2.53% 79.64%

Capital Gain Distribution Analysis

BBC Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Dividend Payout History

View More +

BBC - Fund Manager Analysis

Managers

Matthew Brown


Start Date

Tenure

Tenure Rank

Aug 14, 2017

3.22

3.2%

Matthew Brown serves as Portfolio Manager at Virtus ETF Advisers LL. Mr. Brown is also executive managing director and chief operating officer at Virtus ETF Solutions LLC (“VES”) since 2012. Before founding VES in 2012, he served as director of operations for Factor Advisors from 2010 to 2012. In 2009, Mr. Brown co-founded ETP Resources, a consulting and data services business that continues to grow and serve the ETF industry. From 2008 to 2009, he headed U.S. operations and served as chief compliance officer for U.K.-based issuer SPA/London & Capital. Mr. Brown earned a B.A. in Economics from Boston College.

Seth Kadushin


Start Date

Tenure

Tenure Rank

Aug 14, 2017

3.22

3.2%

Seth Kadushin serves as Portfolio Manager at Virtus ETF Advisers LLC. Mr. Kadushin has also served as director of capital markets at Virtus ETF Solutions LLC (“VES”) since 2013. Prior to joining VES, Mr. Kadushin worked at Euromoney Institutional Investor, Plc where he developed large scale investment management programs focusing on Exchange Traded Instruments and Alternate Investment Strategies. From 2011 through 2012 Mr. Kadushin worked at Wedbush Securities as an Options Desk Strategist. Mr. Kadushin worked at RBS Securities as Head Program Trader from 2009 through 2011. Prior to 2009, Mr. Kadushin held senior level positions at Lehman Brothers and Bear Sterns (J.P. Morgan), where he was a member of the firm’s Cross Asset Policy Committee charged with instituting their equity trading division’s guidelines. Mr. Kadushin holds a BBA in Finance from Emory University. He achieved his Master’s in Business from Fordham University with a concentration in Information Systems.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.09 23.14 7.28 20.52

Continue to site >
Trending ETFs